

These criteria apply to the following:			
<input type="checkbox"/> ACF	<input type="checkbox"/> SF	<input type="checkbox"/> MMT	<input type="checkbox"/> Aetna FI ACF
<input type="checkbox"/> ACFC	<input type="checkbox"/> SFC	✓ Marketplace (MF)	<input type="checkbox"/> Aetna FI ACFC
<input type="checkbox"/> ACCF	<input type="checkbox"/> SCCF	✓ Aetna SG ACA (Aetna Health Exchanges)	<input type="checkbox"/> Aetna FI SOO
<input type="checkbox"/> BC	<input type="checkbox"/> VF	✓ Aetna IVL	
<input type="checkbox"/> BCC	<input type="checkbox"/> VFC		

EXCEPTION CRITERIA

ED EXCEPTION CRITERIA

BRAND NAME

(generic)

ALPROSTADILS:

CAVERJECT
(alprostadil)

EDEX
(alprostadil)

MUSE
(alprostadil)

PHOSPHODIESTERASE

TYPE 5 (PDE-5) INHIBITORS:

CHEWTADZY (10mg and 20mg only)
(tadalafil chewable tablets)

CIALIS (10mg and 20mg only)
(tadalafil)

STENDRA
(avanafil)

(vardenafil)

(vardenafil orally disintegrating tablet)

VIAGRA
(sildenafil)

Status: CVS Caremark® Criteria

Type: Exception Criteria

These criteria apply to the following:			
<input type="checkbox"/> ACF	<input type="checkbox"/> SF	<input type="checkbox"/> MMT	<input type="checkbox"/> Aetna FI ACF
<input type="checkbox"/> ACFC	<input type="checkbox"/> SFC	✓ Marketplace (MF)	<input type="checkbox"/> Aetna FI ACFC
<input type="checkbox"/> ACCF	<input type="checkbox"/> SCCF	✓ Aetna SG ACA (Aetna Health Exchanges)	<input type="checkbox"/> Aetna FI SOO
<input type="checkbox"/> BC	<input type="checkbox"/> VF	✓ Aetna IVL	
<input type="checkbox"/> BCC	<input type="checkbox"/> VFC		

POLICY

FDA-APPROVED INDICATION

ALPROSTADILS

Caverject

Erectile Dysfunction

Caverject is indicated for the treatment of erectile dysfunction.

Diagnostic Test

Caverject is indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

Edex

Edex is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Muse

Muse is indicated for the treatment of erectile dysfunction. Studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with similarly administered placebo.

PHOSPHODIESTERASE TYPE 5 (PDE-5) INHIBITORS

Chewtadzy

Erectile Dysfunction

Chewtadzy is indicated for the treatment of erectile dysfunction (ED) in adult males.

Benign Prostatic Hyperplasia

Chewtadzy is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males.

Erectile Dysfunction and Benign Prostatic Hyperplasia

Chewtadzy is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH) in adult males.

Limitations of Use

If Chewtadzy is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown.

Chewtadzy is not indicated for once daily use for ED because dosing is not possible in such patients (the recommended dosage for this indication cannot be achieved with the lowest available strength).

Cialis

Erectile Dysfunction

Cialis is indicated for the treatment of erectile dysfunction (ED).

Benign Prostatic Hyperplasia

Cialis is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Erectile Dysfunction and Benign Prostatic Hyperplasia

Cialis is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).

Limitation of Use

ED Exception (Aetna SG ACA, Aetna IVL, MF) Policy UDR 05-2024 v2.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

These criteria apply to the following:			
<input type="checkbox"/> ACF	<input type="checkbox"/> SF	<input type="checkbox"/> MMT	<input type="checkbox"/> Aetna FI ACF
<input type="checkbox"/> ACFC	<input type="checkbox"/> SFC	✓ Marketplace (MF)	<input type="checkbox"/> Aetna FI ACFC
<input type="checkbox"/> ACCF	<input type="checkbox"/> SCCF	✓ Aetna SG ACA (Aetna Health Exchanges)	<input type="checkbox"/> Aetna FI SOO
<input type="checkbox"/> BC	<input type="checkbox"/> VF	✓ Aetna IVL	
<input type="checkbox"/> BCC	<input type="checkbox"/> VFC		

If Cialis is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Cialis decreases from 4 weeks until 26 weeks, and the incremental benefit of Cialis beyond 26 weeks is unknown.

Stendra

Stendra is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males.

Vardenafil

Vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction.

Vardenafil orally disintegrating tablet

Vardenafil hydrochloride orally disintegrating tablet is indicated for the treatment of erectile dysfunction.

Viagra

Viagra is indicated for the treatment of erectile dysfunction.

COVERAGE CRITERIA

Erectile Dysfunction

Authorization may be granted when the requested drug is being prescribed for erectile dysfunction.

QUANTITY LIMITS APPLY

6 units per 25 days* or 18 units per 75 days*

**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

DURATION OF APPROVAL (DOA)

- 1716-C: DOA: 12 months

REFERENCES

1. Caverject [package insert]. New York, NY: Pharmacia and Upjohn Company; March 2023.
2. Caverject Impulse [package insert]. New York, NY: Pharmacia and Upjohn Company; December 2022.
3. Chewtadzy [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc. June 2024
4. Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2023.
5. Edex [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; July 2018.
6. Muse [package insert]. Somerset, New Jersey: Meda Pharmaceuticals; April 2018.
7. Vardenafil Hydrochloride Film-coated Tablet [package insert]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc.; May 2023.
8. Vardenafil Hydrochloride Tablet [package insert]. Congers, NY: Chartwell RX, LLC.; February 2024.
9. Vardenafil Hydrochloride Orally Disintegrating Tablet [package insert]. Princeton, NJ: Macleods Pharma USA, Inc.; September 2023.
10. Stendra [package insert]. Freehold, NJ: Metuchen Pharmaceuticals, LLC; October 2022.
11. Viagra [package insert]. New York, NY: Pfizer Labs; December 2017.
12. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed April , 2024.
13. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/ /2024).

ED Exception (Aetna SG ACA, Aetna IVL, MF) Policy UDR 05-2024 v2.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

These criteria apply to the following:			
<input type="checkbox"/> ACF	<input type="checkbox"/> SF	<input type="checkbox"/> MMT	<input type="checkbox"/> Aetna FI ACF
<input type="checkbox"/> ACFC	<input type="checkbox"/> SFC	✓ Marketplace (MF)	<input type="checkbox"/> Aetna FI ACFC
<input type="checkbox"/> ACCF	<input type="checkbox"/> SCCF	✓ Aetna SG ACA (Aetna Health Exchanges)	<input type="checkbox"/> Aetna FI SOO
<input type="checkbox"/> BC	<input type="checkbox"/> VF	✓ Aetna IVL	
<input type="checkbox"/> BCC	<input type="checkbox"/> VFC		

14. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. *J Urol*. 2018; 200: 633-641.
15. Eisenberg M, Shindel A, Smith J, et al. Socioeconomic, Anthropomorphic, and Demographic Predictors of Adult Sexual Activity in The United States: Data from the National Survey of Family Growth. *J Sex Med*. 2010;7:50-58.
16. Lindau S, Schumm L, Laumann E, et al. A Study of Sexuality and Health among Older Adults in the United States *N Engl J Med*. 2007 August 23;357(8):762–774.
17. Ueda P, Mercer CH, Ghaznavi C, et al. Trends in Frequency of Sexual Activity and Number of Sexual Partners Among Adults Aged 18-44 Years in the US, 2000-2018. *JAMA Network Open*. 2020 June 12; 3(6): e203833.
18. Twenge JM, Sherman RA, Wells BE. Declines in Sexual Frequency Among American Adults, 1989–2014. *Arch Sex Behav*. 2017;46(8):2389-2401.

ED Exception (Aetna SG ACA, Aetna IVL, MF) Policy UDR 05-2024 v2.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423